Page 5 - Database Consortium News Today

Triplet therapy for advanced renal cell carcinoma may soon be an option, after results show that adding cabozantinib to dual immune checkpoint inhibition improved progression-free survival.

– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab –– Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 month...

Patients treated with the three-drug combination had a 27% lower risk of progression or death compared to those on the two immunotherapy drugs.

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.

08.09.2022 - Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from COSMIC-313, an ongoing phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in ...

- Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab - - Median progression-free

Research needed to examine role of nephrectomy in the era of modern immunotherapy combos

The evolution in systemic therapies for metastatic kidney cancer improved overall survival in a study of real-world patients.

The evolution in systemic therapies for metastatic kidney cancer improved overall survival in a study of real-world patients.

Real-world data confirm pazopanib to be safe and effective in patients with metastatic renal cell carcinoma.